Go Pro
OTCMKTS:BAYRY

Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis

Bayer Aktiengesellschaft logo
$13.89 -0.08 (-0.57%)
As of 07/31/2026 04:00 PM Eastern

About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY)

Advanced

Key Stats

Today's Range
$13.69
$13.92
50-Day Range
$9.88
$15.19
52-Week Range
$7.19
$15.23
Volume
385,207 shs
Average Volume
771,765 shs
Market Capitalization
$54.59 billion
P/E Ratio
N/A
Dividend Yield
0.14%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates. Its Consumer Health segment produces and markets nonprescription medicines and self-care products intended for a broad global audience. The Crop Science division supplies seeds, crop protection products and digital farming tools to farmers and agribusinesses, integrating agronomic services with chemical and seed portfolios to address productivity and sustainability challenges.

Key historical milestones include the company’s founding in the 19th century and substantial expansion through acquisitions, most notably the 2018 purchase of Monsanto, which significantly expanded Bayer’s seed and crop protection footprint. That acquisition also brought high-profile legal and regulatory matters related to glyphosate-based products, which have been a notable element of the company’s recent corporate history. Bayer conducts operations across Europe, the Americas, Asia-Pacific and other regions, with global manufacturing, research centers and commercial organizations.

Bayer is governed by a board of management and a supervisory board and invests heavily in research and development to sustain long-term product pipelines in health and agriculture. The company’s activities emphasize innovation, regulatory compliance and global market presence while navigating complex legal, environmental and commercial landscapes typical for a multinational life sciences firm.

AI Generated. May Contain Errors.

Bayer Aktiengesellschaft Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

BAYRY MarketRank™: 

Bayer Aktiengesellschaft scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bayer Aktiengesellschaft has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bayer Aktiengesellschaft's stock forecast and price target.
  • Earnings Growth

    Earnings for Bayer Aktiengesellschaft are expected to grow by 5.60% in the coming year, from $1.25 to $1.32 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bayer Aktiengesellschaft is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bayer Aktiengesellschaft is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bayer Aktiengesellschaft has a PEG Ratio of 4.46. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bayer Aktiengesellschaft has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bayer Aktiengesellschaft's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of Bayer Aktiengesellschaft has been sold short.
  • Short Interest Ratio / Days to Cover

    Bayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bayer Aktiengesellschaft has recently increased by 88.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bayer Aktiengesellschaft has a dividend yield of 0.17%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Bayer Aktiengesellschaft does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.52% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.

  • Read more about Bayer Aktiengesellschaft's dividend.
  • News Sentiment

    Bayer Aktiengesellschaft has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Bayer Aktiengesellschaft this week, compared to 5 articles on an average week.
  • Search Interest

    Only 5 people have searched for BAYRY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days.
Receive BAYRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BAYRY Stock News Headlines

Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Headlines

BAYRY Stock Analysis - Frequently Asked Questions

Bayer Aktiengesellschaft's stock was trading at $10.82 at the start of the year. Since then, BAYRY shares have increased by 28.4% and is now trading at $13.89.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) announced its earnings results on Tuesday, May, 12th. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.15. The company earned $15.73 billion during the quarter, compared to analysts' expectations of $15.77 billion. Bayer Aktiengesellschaft had a positive trailing twelve-month return on equity of 17.61% and a negative net margin of 4.75%.

Bayer Aktiengesellschaft subsidiaries include these companies: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and more.

Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2026
Today
8/01/2026
Next Earnings (Estimated)
8/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:BAYRY
CIK
1144145
Employees
88,078
Year Founded
1863

Profitability

EPS (Trailing Twelve Months)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
11.11
P/E Growth
4.46
Net Income
-$4.10 billion
Net Margins
-4.75%
Pretax Margin
-3.75%
Return on Equity
17.61%
Return on Assets
4.81%

Debt

Debt-to-Equity Ratio
1.06
Current Ratio
1.05
Quick Ratio
0.70

Sales & Book Value

Annual Sales
$51.55 billion
Price / Sales
1.06
Cash Flow
$2.18 per share
Price / Cash Flow
6.36
Book Value
$7.50 per share
Price / Book
1.85

Miscellaneous

Outstanding Shares
3,930,000,000
Free Float
N/A
Market Cap
$54.59 billion
Optionable
Not Optionable
Beta
0.55

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (OTCMKTS:BAYRY) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners